- Home
- MBOT vs HCWB Comparison
MBOT vs HCWB Comparison
Compare MBOT & HCWB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MBOT | HCWB |
|---|---|---|
| Founded | 2010 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 126.3M | 5.5M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | MBOT | HCWB |
|---|---|---|
| Price | $1.99 | $0.99 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 1 |
| Target Price | $8.75 | ★ $35.00 |
| AVG Volume (30 Days) | ★ 2.0M | 47.9K |
| Earning Date | 11-12-2025 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $422,026.00 |
| Revenue This Year | N/A | $178.64 |
| Revenue Next Year | $3,119.61 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.08 | $1.11 |
| 52 Week High | $4.67 | $41.20 |
Technical Indicators
Market Signals| Indicator | MBOT | HCWB |
|---|---|---|
| Relative Strength Index (RSI) | 38.43 | 18.53 |
| Support Level | $2.06 | $1.53 |
| Resistance Level | $2.14 | $1.69 |
| Average True Range (ATR) | 0.12 | 0.17 |
| MACD | -0.02 | -0.02 |
| Stochastic Oscillator | 5.83 | 2.83 |
Price Performance
Historical ComparisonAbout MBOT Microbot Medical Inc.
Microbot Medical Inc is a breakthrough medical device company. The group is focused on transforming endovascular procedures through advanced robotic technology. Microbot's LIBERTY Endovascular Robotic System is the first single-use, remotely operated robotic solution designed for precision, efficiency and provider safety. With a robust intellectual property portfolio and a deep commitment to innovation, Microbot is shaping the future of endovascular care.
About HCWB HCW Biologics Inc.
HCW Biologics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen the health span by disrupting the link between chronic, low-grade inflammation and age-related diseases. The company has developed TOBI discovery platform, or Tissue factor-based fusion discovery platform, for the design of category-defining immunotherapeutic drugs. It has selected two molecules as its product candidate; HCW9218 and HCW9302. HCW9218 is a bifunctional immunotherapeutic designed with the capabilities to neutralize transforming growth and stimulate immune cells. HCW9302 is designed to activate and expand regulatory T cells, which deactivate inflammasomes.